IMS 2022 | Phase I study of ABBV383, a novel BCMAxCD3 bispecific antibody, in R/R multiple myeloma
Ravi Vij
• 27 Aug 2022
Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, comments on the design, safety, and preliminary results of a Phase I study evaluating ABBV383, a novel BCMAxCD3 bispecific antibody designed to reduce the risk of developing cytokine release syndrome (CRS) in patients with relapsed/refractory (R/R) multiple myeloma. Overall, the study reported that this drug was well tolerated. Further investigations on the efficacy of this drug at different doses are ongoing. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
